Article
Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.
Antiviral research - 1 Jan 2014
Deest Maximilian, Westhaus Sandra, Steinmann Eike, Manns Michael P, von Hahn Thomas, Ciesek Sandra
Abstract excerpt
End stage liver disease caused by chronic infection with the hepatitis C virus (HCV) is a leading indication for liver transplantation, yet outcomes are poor since the liver graft is rapidly re-infected by HCV. Antibodies against the essential HCV receptor CD81 have been shown to inhibit HCV cell entry in vitro and in vivo and may represent an attractive treatment option. However, several CD81 variants exist at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
